Panacea Innovation Ltd

CIK: 0002010692

Transaction Breakdown

Open Market Buys (P)2 (25.0%)

High conviction signal

Open Market Sales (S)2 (25.0%)

Position reduction

Option Exercises (M)2 (25.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ATRA

Atara Biotherapeutics, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (8 total)

ATRA
Atara Biotherapeutics, Inc.
May 7, 2026
Sale(S)
Indirect
313.4K shares at avg. $10.10$3.2M
ATRA
Atara Biotherapeutics, Inc.
Mar 17, 2026
Exercise(M)
Indirect
259.2K shares at avg. $0.00$25.916
ATRA
Atara Biotherapeutics, Inc.
Mar 17, 2026
Tax Payment(F)
Indirect
5 shares at avg. $5.23$26.15
ATRA
Atara Biotherapeutics, Inc.
Jan 12, 2026
Sale(S)
Indirect
80.6K shares at avg. $6.07$489K
ATRA
Atara Biotherapeutics, Inc.
Nov 28, 2025
Exercise(M)
Indirect
48.7K shares at avg. $0.00$4.874
ATRA
Atara Biotherapeutics, Inc.
Nov 28, 2025
Tax Payment(F)
Indirect
1 shares at avg. $14.03$14.03
ATRA
Atara Biotherapeutics, Inc.
Aug 15, 2025
Purchase(P)
Indirect
55K shares at avg. $12.19$670K
ATRA
Atara Biotherapeutics, Inc.
Jul 17, 2025
Purchase(P)
Indirect
19.3K shares at avg. $9.64$186K

		Type	Shares	Price		Ownership
May 7, 2026	ATRA Atara Biotherapeutics, Inc.	Sale(S)	313,446	$10.10	$3,165,021	Indirect
Mar 17, 2026	ATRA Atara Biotherapeutics, Inc.	Exercise(M)	259,163	$0.00	$26	Indirect
Mar 17, 2026	ATRA Atara Biotherapeutics, Inc.	Tax Payment(F)	5	$5.23	$26	Indirect
Jan 12, 2026	ATRA Atara Biotherapeutics, Inc.	Sale(S)	80,554	$6.07	$489,019	Indirect
Nov 28, 2025	ATRA Atara Biotherapeutics, Inc.	Exercise(M)	48,737	$0.00	$5	Indirect
Nov 28, 2025	ATRA Atara Biotherapeutics, Inc.	Tax Payment(F)	1	$14.03	$14	Indirect
Aug 15, 2025	ATRA Atara Biotherapeutics, Inc.	Purchase(P)	55,000	$12.19	$670,423	Indirect
Jul 17, 2025	ATRA Atara Biotherapeutics, Inc.	Purchase(P)	19,335	$9.64	$186,372	Indirect

1-8 of 8 transactions

About Panacea Innovation Ltd

Panacea Innovation Ltd (SEC CIK 0002010692) files insider reports with the SEC as 10% Owner of Atara Biotherapeutics, Inc. (ATRA).

Signal8 holds 7 ownership filings by Panacea Innovation Ltd (1 Form 3, 6 Form 4), filed between May 21, 2025 and May 11, 2026. Those filings report 8 transactions, from Jul 17, 2025 to May 7, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Panacea Innovation Ltd's filings is in GRAND CAYMAN.

Recent filings by Panacea Innovation Ltd

May 7, 2026: Open-market sale of ATRA shares (Form 4, code S).
Mar 17, 2026: Option exercise of ATRA shares (Form 4, code M).
Mar 17, 2026: Tax withholding of ATRA shares (Form 4, code F).
Jan 12, 2026: Open-market sale of ATRA shares (Form 4, code S).
Nov 28, 2025: Option exercise of ATRA shares (Form 4, code M).

Other insiders filing for Atara Biotherapeutics, Inc. (ATRA)

Cherry Brian N, Director
Nguyen AnhCo, President and CEO
Redmile Group, LLC, Director
Sarney Kevin G, Interim CFO
HEIDEN WILLIAM K, Director
Fust Matthew K, Director

How to read Form 4 transaction codes